Discontinued — last reported Q3 '25
Albemarle Equity Method Investments increased by 15.6% to $948.09M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 28.9%, from $735.77M to $948.09M. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows an upward trend with a 4.6% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $907.08M | $902.50M | $912.01M | $937.62M | $903.86M | $1.16B | $1.15B | $1.39B | $1.62B | $1.25B | $1.37B | $1.26B | $1.16B | $1.18B | $1.12B | $735.77M | $820.93M | $838.73M | $819.85M | $948.09M |
| QoQ Change | — | -0.5% | +1.1% | +2.8% | -3.6% | +28.2% | -0.7% | +20.9% | +16.5% | -22.7% | +9.2% | -8.1% | -7.8% | +1.6% | -5.2% | -34.2% | +11.6% | +2.2% | -2.3% | +15.6% |
| YoY Change | — | — | — | — | -0.4% | +28.4% | +26.2% | +48.4% | +79.4% | +8.2% | +19.1% | -9.5% | -28.4% | -5.9% | -18.4% | -41.6% | -29.3% | -28.9% | -26.7% | +28.9% |
| Segment | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|
| Energy Storage | — | $585.65M | $663.22M | $676.84M | $737.79M | $894.97M |
| Ketjen | $140.92M | $150.12M | $157.71M | $161.89M | — | — |
| Total | $1.12B | $735.77M | $820.93M | $838.73M | $819.85M | $948.09M |
Ketjen was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.